AI-discovered rentosertib lowered biological age on six aging clocks in lung disease trial
According to Insilico Medicine data published in Nature Biotechnology, the AI-discovered IPF drug rentosertib made treated patients appear younger on six proteomic aging clocks in a 12-week Phase 2a trial. Expert commentary says the result is early and far from proven anti-aging; the news spread from 7 September 2026.
Who is affected and how
- pharmaceuticals
- Using aging clocks as secondary endpoints is a new trial-design option, but it needs validation.
- doctor
- When answering pulmonary fibrosis patients, present the aging-clock result as biomarker data, not as evidence of clinical benefit.
- health policy
- Whether regulators will accept biological age as an endpoint will sooner or later reach the agenda.
Sources
- AI-designed drug candidate reverses biological age in clinical studynews-medical · Sep 7, 2026
- AI-Designed Drug Reverses Biological Age: All 6 Aging Clocks Decline in 43-Patient Trialbiggo finance · Sep 7, 2026
- Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trialthe next web · Sep 7, 2026
- HK-listed firm-developed AI lung drug reverses aging markers in studychinadailyhk.com · Sep 7, 2026
- AI-Developed Rentosertib Shows Potential to Lower Biological Age in Clinical Trial - RobotTodayrobottoday.com · Sep 7, 2026
- AI-Designed Drug Shows Reversal of Aging Markers in Lung Disease Trial | AI Glimpseaiglimpse.ai · Sep 7, 2026
- Insilico's AI-designed lung drug lowered predicted… | Pivot Newspivotnews.ai · Sep 7, 2026
- AI-Discovered Lung Drug Reverses Aging Markers in Study - Bloomberg.combloomberg.com · Sep 8, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.